COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA

COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA

Comparative pharmacoeconomic analysis of fixed-dose combinations (FDC) vilanterol / fluticasone furoate vs budesonide / formoterol was needed to identify the preferable FDC for asthma management.Study objective: to identify the preferable FDC of inhaled corticosteroid/ longacting beta agonist combin...

Full description

Bibliographic Details
Main Authors:	N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2017-08-01
Series:	Фармакоэкономика
Subjects:	asthma inhaled corticosteroids ics long-acting beta agonists laba vilanterol fluticasone furoate budesonide formoterol fixed-dose combination cost-minimization analysis budget impact analysis
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/195

Similar Items

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
by: Covelli H, et al.
Published: (2015-12-01)

Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma
by: Akira Umeda, et al.
Published: (2019-01-01)

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
by: Janson C, et al.
Published: (2017-10-01)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
by: Tsan-Ming Huang, et al.
Published: (2020-09-01)

The effectiveness of single inhaler triple therapy in patients with bronchial asthma in real clinical practice
by: V. V. Naumova, et al.
Published: (2022-04-01)

Modeled small airways lung deposition of two fixed-dose triple therapy combinations assessed with in silico functional respiratory imaging
by: Omar Usmani, et al.
Published: (2023-09-01)

Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma
by: Bollmeier SG, et al.
Published: (2016-05-01)

Rational therapy of asthma in children with inhaled corticosteroids
by: N. A. Geppe, et al.
Published: (2016-12-01)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
by: Perrone V, et al.
Published: (2016-11-01)

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
by: Akira Umeda, et al.
Published: (2023-04-01)

Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review
by: A. A. Viesel, et al.
Published: (2022-01-01)

In Vitro Analysis of Nine MicroRNAs in CD8+ T Cells of Asthmatic Patients and the Effects of Two FDA-approved Drugs
by: Mohsen Badalzadeh, et al.
Published: (2019-08-01)

Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma
by: Roberto W. Dal Negro, et al.
Published: (2018-06-01)

Inhaled corticosteroid for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
by: Chin-Wei Hsu, et al.
Published: (2023-10-01)

An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing
by: L Meyer, et al.
Published: (2003-05-01)

Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial
by: Peter Daley-Yates, et al.
Published: (2022-09-01)

Inhaled Corticosteroids and the Risk of Nontuberculous Mycobacterial Pulmonary Disease in Chronic Obstructive Pulmonary Disease: Findings from a Nationwide Population-Based Study
by: Iseul Yu, et al.
Published: (2023-06-01)

In vitro Antibacterial Activity of Mometasone Furoate, Fluticasone Propionate and Fluticasone Furoate Nasal Preparations Against Streptococcus pneumoniae, Hemophilus influenzae, Streptococcus viridans, Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli
by: Philip Lance A. Liu, et al.
Published: (2010-06-01)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
by: Woodcock Ashley, et al.
Published: (2011-12-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01)

Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
by: Nan Shang, et al.
Published: (2024-12-01)

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective
by: Schroeder M, et al.
Published: (2020-07-01)

A Comparison of Long-Term Anti-Inflammatory Effect of Two ICS/LABA Combination Inhalers; Fix-Dosed Maintenance Therapy with Budesonide/Formoterol and Salmeterol/Fluticasone
by: Masayuki Hojo, et al.
Published: (2014-01-01)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
by: Bernstein David I, et al.
Published: (2011-12-01)

Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial
by: Ana Luisa Godoy Fernandes, et al.
Published: (2001-09-01)

An Indian perspective on the use of fluticasone/formoterol in asthma and chronic obstructive pulmonary disease patients
by: Rahul Sharma, et al.
Published: (2021-01-01)

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
by: Donald P. Tashkin, et al.
Published: (2018-10-01)

Risk of Tuberculosis Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Study
by: Iseul Yu, et al.
Published: (2022-07-01)

Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
by: Choi JH, et al.
Published: (2021-11-01)

Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS
by: Vallejo-Aparicio LA, et al.
Published: (2018-09-01)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
by: Yousif S. Alakeel, et al.
Published: (2022-03-01)

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study
by: Hélène Salvator, et al.
Published: (2024-01-01)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β2-Agonist–Inhaled Corticosteroid Rescue
by: Lugogo N, et al.
Published: (2023-05-01)

Effect of Switching from Salmeterol/Fluticasone to Formoterol/Budesonide Combinations in Patients with Uncontrolled Asthma
by: Taisuke Akamatsu, et al.
Published: (2012-01-01)

Pharmacoeconomic aspects of bronchial asthma therapy: real clinical practice
by: A. S. Belevsky, et al.
Published: (2018-10-01)

Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study
by: Daniel Dedman, et al.
Published: (2019-04-01)

Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study
by: Lee JH, et al.
Published: (2020-12-01)

EARLY PRESCRIPTION OF INHALATION CORTICOSTEROID IN BRONCHIAL ASTHMA
by: Z. R. Aisanov, et al.
Published: (2017-11-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
by: Micheletto C, et al.
Published: (2019-09-01)